OOIR: Observatory of International Research

Papers

(The H4-Index of Seminars in Cancer Biology is 78. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)

Article	Citations
Editorial Board	445
Advances in biology and novel treatments of SCLC	431
Small secretory proteins of immune cells can modulate gynecological cancers	327
Unveiling the role of PIK3R1 in cancer: A comprehensive review of regulatory signaling and therapeutic implications	255
Critical DNA damaging pathways in tumorigenesis	237
Emerging applications of bacteria as antitumor agents	230
Deregulated transcription factors in the emerging cancer hallmarks	218
Updated review on green tea polyphenol epigallocatechin-3-gallate as a cancer epigenetic regulator	217
Carbonic anhydrase IX: A tumor acidification switch in heterogeneity and chemokine regulation	215
The molecular chaperone TRAP1 in cancer: From the basics of biology to pharmacological targeting	209
Biology of cancer; from cellular and molecular mechanisms to developmental processes and adaptation	199
Targeting Hippo signaling pathway by phytochemicals in cancer therapy	188
Multifaceted role of chemokines in solid tumors: From biology to therapy	185
Editorial Board	182
Editorial Board	180
PIWI-interacting RNAs in human cancer	179
Origins and molecular effects of hypoxia in cancer	177
Molecular targets of tyrosine kinase inhibitors in thyroid cancer	171
Excess body weight and postmenopausal breast cancer: Emerging molecular mechanisms and perspectives	170
The IL-1 family in tumorigenesis and antitumor immunity	169
Erratum to “RNA regulatory mechanisms controlling TGF-β signaling and EMT in cancer” [Semin. Cancer Biol. 102–103 (2024) 4–16]	167
Special issue: Deregulated transcription factors in the cancer therapeutic challenges: An update on cancer stemness features	157
Targeting micro-environmental pathways by PROTACs as a therapeutic strategy	150
Innovative trial design in precision oncology	149
Immune cellular components and signaling pathways in the tumor microenvironment	141

Multifaceted functions of chronic inflammation in regulating tumor dormancy and relapse	140
Thinking small to win big? A critical review on the potential application of extracellular vesicles for biomarker discovery and new therapeutic approaches in pancreatic cancer	137
Microbiome dysbiosis and epigenetic modulations in lung cancer: From pathogenesis to therapy	137
Association of Chlamydia and Mycoplasma infections with susceptibility to ovarian cancer: A systematic review and meta-analysis	137
Extracellular vesicles associated microRNAs: Their biology and clinical significance as biomarkers in gastrointestinal cancers	134
Enhancing head and neck tumor management with artificial intelligence: Integration and perspectives	134
Targeting monocarboxylate transporters (MCTs) in cancer: How close are we to the clinics?	127
Gut microbes in gastrointestinal cancers	124
Genome chaos: Creating new genomic information essential for cancer macroevolution	122
Anticancer properties of chimeric HDAC and kinase inhibitors	117
New biological and immunological approaches to cancer therapy: Basic and clinical aspects	116
Reprogramming of glycolysis by chemical carcinogens during tumor development	114
Multi-omic markers of intraductal papillary mucinous neoplasms progression into pancreatic cancer	113
Anticancer natural products targeting immune checkpoint protein network	111
Vibrational spectroscopy for decoding cancer microbiota interactions: Current evidence and future perspective	111
Editorial Board	111
Therapy-induced modulation of extracellular vesicles in hepatocellular carcinoma	111
Metabolic landscape and rewiring in normal hematopoiesis, leukemia and aging	110
Insight into the role of multiple signaling pathways in regulating cancer stem cells of gynecologic cancers	109
The role of deiodinases on metabolic alteration in cancer	108
The intricacies of NRF2 regulation in cancer	106
Unravelling the complexities of resistance mechanism in pancreatic cancer: Insights from in vitro and ex-vivo model systems	105
Targeting the “undruggable”: RNA-binding proteins in the spotlight in cancer therapy	105
Cancer cell heterogeneity & plasticity in glioblastoma and brain tumors	104
Extracellular vesicles in glioblastoma: Biomarkers and therapeutic tools	104
Modulation of the tumor microenvironment by natural agents: implications for cancer prevention and therapy	103
How far have we explored fungi to fight cancer?	103
Cellular stress responses and metabolic reprogramming in cancer progression and dormancy	102
Regulation of epithelial-mesenchymal transition by tumor microenvironmental signals and its implication in cancer therapeutics	101
Advancement of cancer immunotherapy using nanoparticles-based nanomedicine	100
Curcumin and colorectal cancer: An update and current perspective on this natural medicine	99
Atrial fibrillation in cancer patients: Epidemiology, identification and management	97
Role of LDH in tumor glycolysis: Regulation of LDHA by small molecules for cancer therapeutics	95
Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer	94
Editorial Board	94
Regulation of the aryl hydrocarbon receptor in cancer and cancer stem cells of gynecological malignancies: An update on signaling pathways	94
Cytotoxic activity of l-lysine alpha-oxidase against leukemia cells	93
Editorial Board	93
The role of RNA processing and regulation in metastatic dormancy	92
Transcription networks rewire gene repertoire to coordinate cellular reprograming in prostate cancer	92
BubR1 and SIRT2: Insights into aneuploidy, aging, and cancer	89
Mechanisms and applications of apolipoproteins and apolipoprotein mimetic peptides: Common pathways in cardiovascular disease and cancer	89
Plant lectins and their usage in preparing targeted nanovaccines for cancer immunotherapy	88
The foundational framework of tumors: Gametogenesis, p53, and cancer	87
The role of tumor microenvironment and exosomes in dormancy and relapse	86
Chaperonins in cancer: Expression, function, and migration in extracellular vesicles	85
Benefits and limitations of nanomedicine treatment of brain cancers and age-dependent neurodegenerative disorders	84
Role of ubiquitination-driven metabolisms in oncogenesis and cancer therapy	84
The microbiome-immune cell interaction network: Advancing tumor immunotherapy	81
Leveraging epigenetic alterations in pancreatic ductal adenocarcinoma for clinical applications	79

Artificial intelligence and pathology: From principles to practice and future applications in histomorphology and molecular profiling	79
Emerging roles of long noncoding RNAs in chemoresistance of pancreatic cancer	79
Epithelial-mesenchymal transition: Insights into nickel-induced lung diseases	78
Analytical demands to use whole-genome sequencing in precision oncology	78
Drivers of centrosome abnormalities: Senescence progression and tumor immune escape	78
Emerging perspectives on growth factor metabolic relationships in the ovarian cancer ascites environment	78
Clinical utility of whole-genome sequencing in precision oncology	78